Literatur
Tsai HM (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235–4244
Furlan M, Robles R, Lammle B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223–4234
Liu L, Choi H, Bernardo A et al (2005) Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 3:2536–2544
Bockmeyer CL, Forstmeier V, Modde F et al (2011) ADAMTS13 – marker of contractile phenotype of arterial smooth muscle cells lost in benign nephrosclerosis. Nephrol Dial Transplant 26:1871–1881
Uemura M, Tatsumi K, Matsumoto M et al (2005) Localization of ADAMTS13 to the stellate cells of human liver. Blood 106:922–924
Manea M, Tati R, Karlsson J et al (2010) Biologically active ADAMTS13 is expressed in renal tubular epithelial cells. Pediatr Nephrol 25:87–96
Budde U, Schneppenheim R (2007) Diagnostik der thrombotischen Mikroangiopathien. In: Bruhn HD, Schambeck CM, Hach-Wunderle V (Hrsg) Hämostaseologie für die Praxis. Schattauer, Stuttgart, S 91–95
Hovinga JA, Studt JD, Alberio L, Lammle B (2004) von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 41:75–82
Kokame K, Nobe Y, Kokubo Y et al (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93–100
Levy GG, Nichols WC, Lian EC et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494
Lotta LA, Garagiola I, Palla R et al (2010) ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 31:11–19
Furlan M, Robles R, Galbusera M et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584
Noris M, Mescia F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8:622–633
George JN (2009) ADAMTS13: what it does, how it works, and why it’s important. Transfusion 49:196–198
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bockmeyer, C., Modde, F. & Becker, J. ADAMTS13 in der Nephrologie. Nephrologe 8, 69–70 (2013). https://doi.org/10.1007/s11560-012-0703-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11560-012-0703-2